What Does Tesamorelin Acetaat Prijs Include on an Australian Research Quote?
When a laboratory records tesamorelin acetaat prijs from a catalogue or quotation, the figure almost always attaches to a labelled vial mass of lyophilised solid, not to a chemistry-corrected peptide mass. That distinction is the first reason quotes are not comparable. A labelled fill of two or five milligrams is a fill-weight claim. The solid contains peptide, acetate counterion, residual water, and possibly residual process solvents or trifluoroacetate if salt exchange was incomplete. Two suppliers can quote the same Australian dollar amount per vial while delivering different net peptide content, so the apparent unit cost diverges once the certificate of analysis is applied.
Australian quotations should state, at minimum: the peptide name and salt form (tesamorelin acetate), labelled fill mass, number of vials, unit price and extended price in AUD, whether GST is included, the lot number or a statement that the lot will be confirmed at dispatch, and which analytical documents ship with the material. Tracked dispatch from local Australian stock should be itemised separately from the material price so freight is not silently folded into a low peptide line. ClaraScience’s research-supply model is local stock, tracked dispatch and batch documentation.
The Dutch search phrasing often assumes a single line price includes a full HPLC–MS package. In Australian research procurement that assumption is unsafe. Some quotes are material-only; others bundle a lot-specific certificate, chromatogram, mass spectrum and counterion statement. A lower headline prijs that omits those files is not cheaper once the receiving laboratory has to confirm identity and purity itself. Record whether the quote is a single lot across all vials. Mixed lots prevent a single net-content factor from being applied and make per-milligram reconciliation messy. Convert overseas lists, brokerage and GST into AUD per documented milligram of peptide after the certificate is in hand, not before.
How Should Net Peptide Content Recast a Tesamorelin Acetate Unit Cost?
Net peptide content is the fraction of the lyophilised solid that is peptide, typically determined by amino acid analysis after hydrolysis, or by nitrogen content using a theoretical nitrogen fraction. It is not the same as HPLC area-percent purity. HPLC purity describes the chromatographic peak distribution of peptide-related species; net peptide content describes how much of the weighed solid is peptide rather than counterion, water and residuals. Both numbers are required before tesamorelin acetaat prijs can be turned into a cost per milligram of peptide.
A worked comparison with illustrative figures, not specifications, shows why. Lot A is quoted at AUD 180 for five milligrams of labelled solid, HPLC purity 98.5 percent, net peptide content 78 percent. Lot B is quoted at AUD 210 for five milligrams, HPLC purity 99.1 percent, net peptide content 88 percent. Cost per labelled milligram favours Lot A. Cost per milligram of peptide is AUD 180 divided by (5 × 0.78) versus AUD 210 divided by (5 × 0.88), which brings the two lots close together and can reverse the ranking if water or acetate differs further. Laboratories that skip net peptide content therefore mis-rank suppliers.
Acetate mass is not negligible for a long analogue, because multiple acetate ions can associate with basic residues. If the certificate reports acetate by ion chromatography as a mass percent, that value should be reconcilable with net peptide content, Karl Fischer water, and any residual trifluoroacetate. A mass-balance check — peptide plus counterion plus water plus residuals approaching 100 percent within method uncertainty — is a documentation quality signal. Quotes that cannot support that check are incomplete rather than inexpensive. Amino acid analysis also functions as an orthogonal composition check: residue mole ratios should match the theoretical composition. Gross deviations suggest a different sequence, a truncated analogue, or a weighing error. When net peptide content is reported without a hydrolysis method, calibration standard or recovery statement, treat the number as unsupported. For multi-vial orders, apply one factor only when every vial shares the lot.
Which HPLC Purity and Related-Substance Fields Should Sit Behind the Quoted Price?
Chromatographic purity is the second correction. Area-normalised HPLC purity at a stated wavelength is not an assay. It excludes non-chromophoric mass such as water and acetate, and it can hide co-eluting related substances if resolution is poor. A research certificate for tesamorelin acetate should state the column chemistry (typically reversed-phase C18), gradient, mobile-phase modifiers, detection wavelength, integration events, and the reporting threshold below which peaks are not listed. Without those parameters, a high percentage figure is not comparable between laboratories.
Related-substance tables matter more than the headline purity when ranking price. Tesamorelin is a long sequence; deletion sequences, insertion errors, oxidation of susceptible residues, deamidation, and incomplete N-terminal modification all appear as satellite peaks. A lot with 98.8 percent main-peak area and a single identified related substance is analytically different from a lot with the same main-peak area and many unidentified peaks. The second lot may require extra method development before it is usable as a reference material, which is a hidden cost not visible in tesamorelin acetaat prijs.
System-suitability data such as tailing factor, plate count, resolution to a critical pair, and replicate peak-area precision tell the buyer whether the purity number was generated under controlled conditions. Chromatograms should be lot-concordant: filename, lot number and sample identifier on the PDF must match the certificate header. Orthogonal mass spectrometry should confirm that the main peak’s molecular ion matches tesamorelin rather than a des-acyl species or a different chain length. Identity literature classifies tesamorelin as a growth hormone-releasing factor analogue (PMID:22298602; PMID:21283099); the receiving laboratory still needs lot-level mass-to-charge evidence. Price comparisons that ignore whether mass spectrometry is included will favour incomplete files. Read any acceptance criteria as the supplier’s internal specification for research material, not as a finished-medicine monograph.
How Is Tesamorelin Identity Confirmed Before a Price Comparison Is Valid?
A unit-cost comparison is meaningless if the solids are not the same chemical entity. Tesamorelin is identified in published evaluations as a synthetic human growth hormone-releasing factor analogue, and the designation TH9507 appears in the same analogue literature (PMID:17086939; PMID:20554713). For laboratory receiving inspection, that classification is background naming; lot identity is established by orthogonal analytical data on the vial in hand.
A typical identity package includes appearance of the lyophilised cake, HPLC retention time against a qualified reference or a historical lot window, electrospray mass spectrometry of the intact peptide with average or monoisotopic mass within a stated tolerance, and, where available, fragment-ion evidence that confirms the N-terminal trans-3-hexenoyl modification and the backbone. The hexenoyl group distinguishes tesamorelin from unmodified GHRH(1–44). A cheaper lot whose mass spectrum is consistent with a des-acyl analogue is not a bargain; it is a different analyte and cannot enter the same prijs ranking.
Counterion identity is part of identity. Acetaat in the trigger query specifies acetate. A certificate that still reports high residual trifluoroacetate after an intended acetate exchange has both a chemistry problem and a mass-balance problem, because the two counterions contribute different mass. Ion chromatography or an equivalent counterion method should be listed when the quote presents tesamorelin as the acetate salt. Laboratories comparing tesamorelin acetaat prijs across vendors should re-price or set aside lots that cannot document the salt form. Amino acid ratios or tandem-mass-spectrometry coverage of terminal peptides reduce the risk that a truncated analogue has been labelled as tesamorelin. These tests are identity controls for research material. Traceability closes the loop: certificate lot number, vial label, invoice line and chromatogram header must agree at dispatch from Australian stock.
How Should Australian Laboratories Rank Tesamorelin Acetate Quotes After Documentation?
Synthesis and purification of a 44-residue, N-terminally modified peptide accumulate deletion sequences, so preparative HPLC and a full related-substance panel are structural cost drivers. When tesamorelin acetaat prijs looks unusually low, the first hypothesis is incomplete purification or a missing analytical package. Acetate exchange after trifluoroacetic-acid cleavage is an extra process step; residual trifluoroacetate, if unquantified, distorts net-peptide-content interpretation. A complete acetate certificate reports acetate content, residual trifluoroacetate where relevant, water, HPLC purity and mass-spectrometric identity. Paying for that panel on the quote is usually cheaper than reproducing it in-house on a small vial. Ask whether the certificate is lot-specific. A generic typical-purity sheet is not a release document.
Build a spreadsheet with one row per quote and columns for supplier, AUD price, GST, labelled milligrams, vial count, lot number, HPLC purity, net peptide content, water, acetate, residual trifluoroacetate, mass-spectrometric identity, chromatogram, related-substance table, dispatch origin, and tracking. Compute Australian dollars per labelled milligram and per net-content-corrected milligram. Rank on the second figure only after identity is a pass/fail gate. Local Australian stock with tracked dispatch removes brokerage uncertainty and shortens the interval between purchase order and lot-document review. ClaraScience positions research peptide supply on those terms plus batch documentation. Hours spent chasing a missing chromatogram are laboratory overhead, so lot-concordant PDFs at dispatch deserve weight in the ranking even when the headline figure is slightly higher. Overseas lists must be brought to AUD after GST and brokerage before they are compared with Australian stock. For multi-vial work, insist on a single lot; split lots destroy a single prijs comparison. Tesamorelin’s published description as a growth hormone-releasing factor analogue does not convert a research vial into a medicine (PMID:22298602; PMID:19243281). Price, purity and identity remain chemical attributes of a characterised solid intended for laboratory research only.
Order Tesamorelin with documentation
If this guide helped you evaluate Tesamorelin for laboratory work, the next step is documented supply: research-grade stock from Australian warehouses, Express tracked shipping, and batch documentation with every order.
Open the Tesamorelin card on the ClaraScience shop for current stock and add-to-cart, or request wholesale access when you need bulk restocks and tier pricing.
Frequently asked questions
Why can two tesamorelin acetaat prijs figures not be compared as raw vial totals?
Because the labelled milligram mass is fill weight, not peptide mass. Acetate, water and residuals change net peptide content, and HPLC area-percent is not an assay. Convert each quote to AUD per net-content-corrected milligram after identity passes, using the lot certificate, not the catalogue line.
Does HPLC purity replace net peptide content when ranking tesamorelin acetate price?
No. HPLC purity describes the distribution of peptide-related chromatographic peaks. Net peptide content describes how much of the weighed solid is peptide rather than counterion and water. A high HPLC percentage on a low net-content cake can be more expensive per milligram of peptide than a slightly lower HPLC percentage on a better-documented acetate lot.
Which certificate fields should an Australian tesamorelin acetate quote include?
Lot number concordant with the vial label, HPLC purity with method parameters and a related-substance table, mass-spectrometric identity, water, acetate content, residual trifluoroacetate if relevant, and the chromatogram PDF. Tracked dispatch from Australian stock and a single-lot statement for multi-vial orders should sit on the quotation itself.
How does the acetate salt form change apparent milligram cost?
Acetate contributes real mass. If two lots have different acetate percentages, the same labelled fill contains different peptide mass. Residual trifluoroacetate after incomplete exchange adds a second counterion and breaks mass balance. Documented acetate lots should be compared on net peptide content, not on fill weight alone.
Is tesamorelin the same analyte as unmodified GHRH(1–44)?
No. Tesamorelin is described as a synthetic growth hormone-releasing factor analogue (PMID:19243281; PMID:17086939). Lot identity should confirm the intact mass, including the N-terminal hexenoyl modification. A des-acyl mass spectrum is a different chemical entity and must not be ranked on the same prijs table.
Does a lower overseas list beat Australian stock on tesamorelin acetate?
Not until brokerage, GST, documentation completeness and net peptide content are applied. Local Australian stock with tracked dispatch and lot-concordant certificates often produces a lower true unit cost and a shorter path to receiving inspection, even when the headline foreign prijs looks smaller.
References
- PMID:17086939 — Drug evaluation: tesamorelin, a synthetic human growth hormone releasing factor — Curr Opin Investig Drugs — 2006
- PMID:19243281 — Tesamorelin, a human growth hormone releasing factor analogue — Expert Opin Investig Drugs — 2009
- PMID:22298602 — Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy — Ann Pharmacother — 2012
- PMID:21283099 — Tesamorelin — Nat Rev Drug Discov — 2011
- PMID:20554713 — Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data — J Clin Endocrinol Metab — 2010
Research use only
This article is provided for laboratory research and educational purposes only. Products referenced are not for human or veterinary use. ClaraScience makes no therapeutic, medical, or efficacy claims, and nothing here constitutes medical advice.
